Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations.

ABSTRACT: Losses of 5-10% or more of initial body weight are associated with improvements in obesity-related comorbidities. However, attaining and sustaining this level of weight loss is challenging. The novel anti-obesity medication semaglutide 2.4 mg injected subcutaneously once weekly as an adjunct to a reduced-calorie diet and physical activity helps patients achieve average losses of 9.6-17.4% of initial body weight at week 68, as well as improvements in cardiometabolic and psychosocial indices. Despite these average benefits, prescribers should carefully assess the suitability of patients for this medication. In this paper, we discuss considerations for the selection of individuals who are candidates for semaglutide and special considerations related to the use of this medication. These includ

SUBMITTER: Chao AM 

PROVIDER: S-EPMC9807016 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature